IP Library Granted Patent US 10,711,295
Granted Patent B2
US 10,711,295 · App. 16/247,323 · Granted Jul 14, 2020

Compositions, kits and related methods for the detection and/or monitoring of salmonella

Inventors: Michael R. Reshatoff (San Diego, CA); Edgar O. Ong (San Diego, CA); James J. Hogan (Coronado, CA)
Assignee: Gen-Probe Incorporated
C12Q1/68C12Q1/689C12Q2304/00Y02A50/451
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,711,295
App. No.
16/247,323
Granted
Jul 14, 2020
Kind
B2
Abstract

Provided are compositions, kits, and methods for the identification of Salmonella. In certain aspects and embodiments, the compositions, kits, and methods may provide improvements in relation to specificity, sensitivity, and speed of detection.

Claims (20)

1. A detection oligonucleotide comprising a nucleotide sequence consisting essentially of the sequence of SEQ ID NO: 66, 67, 68, 69, or 70.

2. The detection oligonucleotide of claim 1 , wherein the oligonucleotide is fluorescently labeled.

3. The detection oligonucleotide of claim 2 , wherein the oligonucleotide comprises a quencher.

4. The detection oligonucleotide of claim 1 , wherein the oligonucleotide is a molecular torch oligonucleotide.

5. A kit comprising a plurality of reagents for detecting a Salmonella target nucleic acid, wherein the plurality of reagents comprises the detection oligonucleotide of claim 1 .

6. The kit of claim 5 , wherein the detection oligonucleotide is fluorescently labeled.

7. The kit of claim 5 , wherein the plurality of reagents further comprises one or more amplification oligonucleotides for amplifying the Salmonella target nucleic acid.

8. The kit of claim 7 , wherein the Salmonella target nucleic acid is an amplicon that comprises a sequence corresponding to bases from about 164 to about 209 of SEQ ID NO: 150.

9. The kit of claim 7 , wherein the one or more amplification oligonucleotides for amplifying the Salmonella target nucleic acid comprises a promoter oligonucleotide for isothermally amplifying the Salmonella target nucleic acid.

10. A nucleic acid complex comprising the detection oligonucleotide of claim 1 hybridized to a Salmonella target nucleic acid.

11. The nucleic acid complex of claim 10 , wherein the detection oligonucleotide is fluorescently labeled.

12. A composition comprising the detection oligonucleotide of claim 1 and one or more amplification and/or capture oligonucleotides for amplifying and/or capturing a Salmonella target nucleic acid.

13. The composition of claim 12 , wherein the detection oligonucleotide is fluorescently labeled.

14. The composition of claim 12 , further comprising one or more amplification oligonucleotides for amplifying a Salmonella target nucleic acid.

15. The composition of claim 12 , further comprising an RNA polymerase.

16. A method for detecting Salmonella in a sample, said method comprising a detecting step of detecting the presence or absence of a Salmonella target nucleic acid using the detection oligonucleotide of claim 1 .

17. The method of claim 16 , wherein the detection oligonucleotide is fluorescently labeled.

18. The method of claim 17 , wherein the detection oligonucleotide further comprises a quencher.

19. The method of claim 16 , wherein the method further comprises amplifying the Salmonella target nucleic acid using one or more amplification oligonucleotides.

20. The method of claim 16 , wherein the Salmonella target nucleic acid is an amplicon that comprises a sequence corresponding to bases from about 164 to about 209 of SEQ ID NO: 150.

Assignments (4)
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 054089/0804 Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO FOCAL THERAPEUTICS, INC.; GEN-PROBE INCORPORATED; FAXITRON BIOPTICS, LLC; GEN-PROBE PRODESSE, INC.
Reel/Frame 075504/0575 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
SECURITY INTEREST Recorded Oct 15, 2020
From: HOLOGIC, INC.; FAXITRON BIOPTICS, LLC; FOCAL THERAPEUTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 054089/0804 →
SECURITY INTEREST Recorded Oct 14, 2019
From: HOLOGIC, INC.; CYNOSURE, LLC; CYTYC CORPORATION; FAXITRON BIOPTICS, LLC; FOCAL THERAPEUTICS, INC.; GEN-PROBE INCORPORATED
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 050719/0701 →